Adagrasib is an oral, small-molecule compound that acts as an inhibitor of KRAS, a protein commonly mutated in cancer. It is supplied as an active pharmaceutical ingredient for use in pharmaceutical manufacturing and research.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing Adagrasib?
Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.
Nalbuphine hydrochloride
pharmaceutical raw material
Sulfachlorpyridazine sodium
pharmaceutical raw material
Sodium sulfaclozine
pharmaceutical raw material
Spectinomycin sulfate
pharmaceutical raw material
The international HS code for Adagrasib (CAS 2326521-71-3) is 2933.59.
2933.59
2933 59 95
Classification per the EU customs inventory ECICS (2026-07 snapshot, HS 2022). National tariff lines and product form can affect the final classification.
2-[(2S)-4-[7-(8-chloronaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile
PEMUGDMSUDYLHU-ZEQRLZLVSA-N
CN1CCC[C@H]1COC2=NC3=C(CCN(C3)C4=CC=CC5=C4C(=CC=C5)Cl)C(=N2)N6CCN([C@H](C6)CC#N)C(=O)C(=C)F
Sourcing Adagrasib?
Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.